Common Stock, par value $0.00033 per share
- Symbol
- PDSB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
PDS Biotechnology Corporation
PDSBNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 21, 2026, the Company updated its corporate presentation deck. A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Company context
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
Current securities
Recent company filings
- Other EventsSep 22, 2026
- SCHEDULE 13D - filed by Nant Capital, LLC regarding PDS Biotechnology CorpSep 21, 2026
- Termination of a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other EventsSep 14, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureSep 8, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 4, 2026
Registered securities in this filing
PDS BIOTECHNOLOGY CORPORATION · 8-K · Filed 2026-09-21
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 21, 2026, the Company updated its corporate presentation deck.
A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference
herein.
Filed exhibits (1)
Exhibit 99.1 Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ: PDSB September 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject …
Open exhibit ↗